New Studies Find Psychedelics Highly Effective in Treating Alcoholism Part 2

New Studies Find Psychedelics Highly Effective in Treating Alcoholism Part 2

Gaia News reports: new studies find psychedelics highly effective in treating alcoholism part 2. Dr. Ben Sessa reveals how MDMA and ketamine offer hope.

Read More

More Details

As clinical research enters a new era, new studies find psychedelics highly effective in treating alcoholism part 2. In this episode of Gaia News (Season 6, Episode 22), Dr. Ben Sessa of Awakn Life Sciences shares how combining specific compounds with psychotherapy could revolutionize addiction recovery. Traditional approaches to substance abuse often fall short, leaving many individuals searching for treatment-resistant alcoholism therapies. This episode examines the clinical studies on psychedelics and alcoholism, focusing on the efficacy of psychedelics in mental health. By exploring how substances like MDMA and ketamine facilitate deep emotional processing, researchers are uncovering new pathways for neuroplasticity and addiction recovery. Dr. Sessa highlights how psychedelic-assisted psychotherapy addresses the root trauma of substance abuse rather than just managing symptoms. While much of the current spotlight is on psilocybin for alcohol use disorder, the integration of MDMA and ketamine into clinical settings represents a parallel breakthrough. This paradigm shift suggests that psychedelic therapy for alcohol addiction is not merely a temporary fix, but a profound catalyst for long-term healing. The discussion centers on the clinical trials conducted by Awakn Life Sciences, where researchers evaluated the safety and efficacy of these compounds when paired with structured therapy sessions. Unlike conventional pharmaceutical interventions that require daily medication, these emerging protocols utilize a limited number of dosing sessions to achieve lasting psychological breakthroughs. Dr. Sessa explains that the therapeutic alliance, combined with the neurobiological effects of these substances, allows patients to confront deep-seated emotional pain without the typical fear response. This dual action of chemical neuroplasticity and psychological support is what makes these modern clinical trials so promising for those who have struggled with chronic dependency.

Key Insights from the Clinical Research

  • The role of MDMA and ketamine in disrupting the neurological loops of addiction.
  • How clinical trials combine pharmacological intervention with intensive psychotherapy.
  • The future of regulatory approval and the integration of these therapies into mainstream medicine.

Begin your exploration into the future of mental health and discover how these groundbreaking scientific advancements are reshaping our understanding of recovery.

Featuring: Dr. Ben Sessa
Audio Languages: English
Subtitles: English
Read More
Testing message will be here